Response, Acute Phase, Survivorship
Conditions
Keywords
Multiple Myeloma, Bortezomib, Thalidomide, Acute Phase Response, Survival
Brief summary
Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
Detailed description
The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators, proteasome inhibitors, etc. The VTD (bortezomib, thalidomide, and dexamethasone) and TD (thalidomide and dexamethasone) regimens are commonly used as a first-line treatment due to limited resources. The study aimed to compare the proportion of favorable responses, survival, and time to the next treatment between two different treatment approaches. The investigators designed a retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
Interventions
DRUGBortezomib
Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)
Sponsors
Hospital General de Mexico
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs.
Exclusion criteria
* Incomplete clinical records * Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues * Clinical records of patients who presented severe sepsis before the beginning of either treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Favorable Response | Post-induction (6 months) | Criteria established with the International Multiple Myeloma Working Group |
| Time to next treatment | Post-induction (2 years) | Need for a secondline treatment after induction |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 3000 days | Survivorship passing 3000 days |
Countries
Mexico
Contacts
Primary ContactChristian O Ramos Peñafiel, PhD
Backup ContactAdán G Gallardo Rodriguez, PhD
Outcome results
None listed